Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors

NCT00881166 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Disease

Interventions

DRUG: MP-470 + topotecan
DRUG: MP-470 + docetaxel
DRUG: MP-470 + erlotinib
DRUG: MP-470 + paclitaxel/carboplatin
DRUG: MP-470 + carboplatin/etoposide

Sponsor

Astex Pharmaceuticals, Inc.